Revolu-zoldonrasib vs placebo for KRAS G12D pancreatic cancer (RMC-9805-305) - Clinical Trial

or email

gi-oncology-cru@dm.duke.edu

¿Quién puede participar en el Estudio?

Grupo etario

Adultos

Detalles del Estudio

Título Completo

[RMC-9805-305] A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC-9805) as First-line Treatment in Patients with Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma (RASolute 305)

Investigador Principal